Adepa Biosciences
Category: Therapeutics
Campus: Ithaca
Incubator:
Adepa Biosciences (formerly Vernx Biotechnology) is developing a range of nutrition products using branched fatty acids (BCFA) for multiple uses: to improve gastrointestinal health in pre-mature and non-premature infants, as a nutritional supplement for adults, and for eventual therapeutic use.
Location: New South Wales, Australia
Foundation Cornell Technology Licensed: 2016
AffyImmune Therapeutics
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
AffyImmune is an immuno-oncology company that develops T cell products for cancer therapy. The company was founded based on intellectual property generated from Weill Cornell Medicine that enables imaging of T cells in patients and T cells to specifically target tumors. The company has two products in the pipeline, and are ready to commence clinical trials in 2018
Location: Natick, MA
Foundation Cornell Technology Licensed: 2017
Akelos, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Akelos Inc. is a biopharmaceutical clinical company developing novel non-opioid, anti-hyperalgesic drugs for the treatment of neuropathic pain. Their compounds are intended to selectively and potently inhibit HCN1 channel activity to limit pain.
Location: New York, New York
Foundation Cornell Technology Licensed: 2018
Angiocrine Bioscience, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Angiocrine Bioscience, Inc., is developing both research and therapeutic products using stem and endothelial cell related technologies.
Location: New York, NY
Foundation Cornell Technology Licensed: 2012
Aufbau Medical Innovations Ltd.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator: Center for Life Science Ventures
Aufbau Medical Innovations is an Irish Operating Company that develops novel therapeutics and diagnostics for ophthalmic diseases.
Location: Dublin, Ireland / Ithaca, NY
Foundation Cornell Technology Licensed: 2020
Convergent Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company’s proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University.
Location: New York
Foundation Cornell Technology Licensed: 1998
Faeth Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Faeth Therapeutics, Inc. is a data-driven, evidence-based healthcare company, with a mission to rethink the role of nutrition in the fight against cancer.
Location: San Francisco, CA
Foundation Cornell Technology Licensed: 2020
Hemogenyx Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Hemogenyx Therapeutics is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow (“BMâ€) failure. The Company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells.
Location: Buffalo, NY
Foundation Cornell Technology Licensed: 2014
IpiNovyx Bio Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
IpiNovyx is a biopharmaceutical company that aims to transform the ways autoimmune and inflammatory are treated through a reversable, ultra-potent and non-toxic approach.
Location: West Nyack, NY
Foundation Cornell Technology Licensed: 2021
Larkspur Biosciences, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Location: Boston, MA
Foundation Cornell Technology Licensed: 2021
LEXEO Therapeutics, LLC
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need.
Location: New York, NY
Foundation Cornell Technology Licensed: 2020
Novita Pharmaceuticals, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Novita Pharmaceuticals, Inc. is a biopharmaceutical startup developing target-specific small molecule drugs to treat cancer metastasis. The company is currently focusing on patients with metastatic breast cancer.
Location: New York, NY
Foundation Cornell Technology Licensed: 2010
Ratio Therapeutics
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers.
Location: New York, NY
Foundation Cornell Technology Licensed: 2021
SACYL Pharmaceuticals
Category: Therapeutics
Campus:
Incubator:
Sacyl Pharmaceuticals (SACYL) aims to develop potent soluble adenylyl cyclase (sAC) inhibitors into first-in-class systemic, non-hormonal, on-demand contraceptives for men and women with the goal to significantly contribute to increased use of modern contraceptives among couples to reduce unintended pregnancies, improving families’ health and well-being globally.
Location: Old Greenwich, CT
Foundation Cornell Technology Licensed: 2023
Sedec Therapeutics, Inc.
Category: Therapeutics
Campus: Ithaca
Incubator:
Sedec is a therapeutics company that aims to inhibit key factors in a subset of CD4+ T cells to decrease inflammation. This approach can be used to treat T cell-mediated autoimmune disorders, such as inflammatory bowel disease.
Location: Boston, MA
Foundation Cornell Technology Licensed: 2021
Stealth BioTherapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Stealth BioTherapeutics, Inc., is a clinical stage, biopharmaceutical company developing novel mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal and metabolic diseases. The company’s first clinical candidate, Bendaviaâ„¢, targets the mitochondria to treat cardio-renal and microvascular impairments.
Location: Newton, MA
Foundation Cornell Technology Licensed: 2006
UbiquiTx, Inc.
Category: Therapeutics
Campus: Ithaca
Incubator:
UbiquiTx, a spin-out from Cornell University and MIT, is focused on leveraging machine learning and protein engineering to develop programmable protein-modulating therapies. The company’s computational platform allows the designing of motif, mutant and PTM-specific peptides to pathogenic proteins from sequence alone based on known interactions found in nature.
Location: Cambridge, MA
Foundation Cornell Technology Licensed: 2022
Versatope Therapeutics, Inc.
Category: Therapeutics
Campus: Ithaca
Incubator:
Versatope Therapeutics is using exosomes (extracellular vesicles) derived from genetically engineered probiotics as a technology platform for the targeted delivery of large molecules used in vaccines, therapeutics and diagnostics. The company has worked with accelerators/incubators MassCONNECT, MassChallenge, and JLABS.
Location: Boston, MA
Foundation Cornell Technology Licensed: 2018
Volastra Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers. The company focuses on developing therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis. The majority of oncology therapeutics target alterations widely found in primary tumors while metastasis is responsible for approximately 90% of cancer deaths. Volastra hopes to change the treatment paradigm for patients by developing novel therapeutics specifically tailored to advanced disease.
Location: New York, NY
Foundation Cornell Technology Licensed: 2019
XyloCor Therapeutics, Inc.
Category: Therapeutics
Campus: Weill Cornell Medicine
Incubator:
XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.
Location: New York, NY
Foundation Cornell Technology Licensed: 2015
